Odyssey Therapeutics closed at $19.50 on Nov 4, down 9.60%, 20.8% below its highest close since Sep 11. Volume of 675.9K shares was 2.68× its 20-day average (well above normal).
Split-adjusted performance: +7.6% over one month.
Short interest was 3.3M shares at the Oct 15 settlement, up 5.7% from the prior report (13.6% of float, 12.4 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ODTXOdyssey Therapeutics | $19.50 | −9.60% | — | — | — | — | $937.1M | |
| GLUEMonte Rosa Therapeutics | $10.82 | +3.94% | −46.9% | −61.3% | −483.9% | — | $923.1M | Compare |
| MGTXMeiraGTx Holdings | $9.42 | −1.05% | −4.8% | +8608.6% | 50.0% | 11.5 | $904.7M | Compare |
| PRMEPrime Medicine | $4.97 | +9.23% | +45.7% | +3.5% | −3649.0% | — | $901.4M | Compare |
| CGEMCullinan Therapeutics | $12.49 | −20.70% | −16.7% | — | — | — | $803.8M | Compare |
| DNAGinkgo Bioworks Holdings | $11.65 | +8.27% | +15.6% | −48.5% | −231.7% | — | $784.5M | Compare |
| SANASana Biotechnology | $2.56 | +4.92% | −29.7% | — | — | — | $766.4M | Compare |
| ATTOAttovia Therapeutics | $15.60 | +2.16% | — | — | — | — | $712.2M | Compare |
| VORVor Biopharma | $20.12 | +1.31% | +26.5% | — | — | 0.9 | $1.24B | Compare |
No recent articles focused on Odyssey Therapeutics.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
